MRK - Merck & Co., Inc.
| Previous close | 84.65 |
| Open | 84.53 |
| Bid | 85.10 x 1100 |
| Ask | 85.60 x 800 |
| Day's range | 84.45 - 85.48 |
| 52-week range | 70.89 - 87.35 |
| Volume | 6,919,172 |
| Avg. volume | 8,147,906 |
| Market cap | 217.096B |
| Beta (3Y monthly) | 0.55 |
| PE ratio (TTM) | 23.83 |
| EPS (TTM) | 3.58 |
| Earnings date | 5 Feb 2020 |
| Forward dividend & yield | 2.20 (2.60%) |
| Ex-dividend date | 2019-09-13 |
| 1y target est | 97.25 |
- Bloomberg
Merck KGaA CFO on M&A Hiatus, Third-Quarter Earnings
Nov.15 -- Marcus Kuhnert, chief financial officer of Merck KGaA, said the company will focus on integrating Versum Materials before it starts looking for a new takeover target. He spoke Nov. 14 on "Bloomberg Markets: European Open" after the firm posted third-quarter earnings.
- Zacks
Medicines Company Up on Rumors of Potential Buyout by Novartis
The Medicines Company (MDCO) is rumored to attract acquisition offers after impressive data readouts from three pivotal studies on PCSK9 inhibitor candidate, inclisiran.
- Business Wire
European Commission Approves Two New Regimens of Merck’s KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC)
KEYTRUDA is the First Anti-PD-1 Therapy Approved in Europe for the First-Line Treatment of Head and Neck Cancer as Monotherapy or in Combination with Chemotherapy, in Patients Whos
- Business Wire
Merck Announces First-Quarter 2020 Dividend
Merck (MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.61 per share of the company’s common stock for the first quarter of 2020. For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions.
- Zacks
Merck's Heart Failure Candidate Meets Goal in Phase III Study
Merck (MRK) and German partner Bayer's vericiguat reduces the risk of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure.
- Zacks
Novo Nordisk Inks Deal With Dicerna to Develop RNAi Therapies
Novo Nordisk (NVO) inks deal with Dicerna Pharmaceuticals to discover and develop novel therapies for the treatment of liver-related cardio-metabolic diseases.
- Zacks
Medicines Company Posts Full Inclisiran Data From ASCVD Study
The Medicines Company (MDCO) reports detailed data from the phase III ORION-10 study on its lead candidate inclisiran to treat patients with ASCVD.
- Zacks
Bristol-Myers Gets FTC Clearance for Celgene Acquisition
Bristol-Myers (BMY) obtains FTC permission for the Celgene acquisition and will divest Otezla to Amgen.
- Zacks
Here's Why AstraZeneca's (AZN) Shares Are Up Year to Date
AstraZeneca's (AZN) stock is on an upward trajectory this year. Let us take a look at the reasons for the same.
- Zacks
5 Blue-Chip Stocks to Buy as Dow Breezes Past 28,000
We highlight blue-chip companies slated to gain in the near term as they have large market capitalization, strong balance sheet and solid cash flow.
- Business Wire
Merck and Bayer’s Investigational Drug Vericiguat Meets Primary Endpoint in Phase 3 Study of Patients with Worsening Chronic Heart Failure
Merck (MRK), known as MSD outside the United States and Canada, today announced that the Phase 3 VICTORIA study evaluating the efficacy and safety of vericiguat, a soluble guanylate cyclase (sGC) stimulator being developed to treat patients with worsening chronic heart failure, has met the primary efficacy endpoint. Vericiguat reduced the risk of the composite endpoint of heart failure hospitalization or cardiovascular death in patients with worsening chronic heart failure with reduced ejection fraction (HFrEF) compared to placebo when given in combination with available heart failure therapies.
- Bloomberg
Thiel Marks Palantir’s Asia Push with $150 Million Japan Venture
(Bloomberg) -- In a rare show of public support, Palantir Technologies Inc.’s co-founder and chairman Peter Thiel pitched the power of the data-mining company during a splashy Tokyo event marking its formal entry into Asia.The billionaire entrepreneur was in Japan Monday to unveil a $150 million, 50-50 joint venture with local financial services firm Sompo Holdings Inc., Palantir Technologies Japan Co. The new company will target government and public sector customers, emphasizing health and cybersecurity initially. Like IBM Corp. and other providers, Palantir’s software pulls together a range of data provided by its customers, mining it for patterns and displaying connections in easy-to-read spiderweb-like graphics that might otherwise get overlooked.“We can learn a lot from Japan, that some of the challenges that Japan has with its aging population are the ones all countries of the West are going to have in the years ahead,” Thiel said at a briefing in Tokyo. “We hoped this can be a two-way exchange.”The push into Asia comes at a critical time for the 15-year-old company. Despite having long-term, billion-dollar contracts with BP Plc., Merck KGaA and others in more than a dozen countries worldwide, Palantir has never turned an annual profit. Under the leadership of Thiel and the management of Chief Executive Officer Alex Karp, Palantir has long emphasized engineering over sales and revenue, a focus that has shifted only this year.The company has not set a date for an initial public offering and continues to explore raising additional funding from private investors. Palantir spokeswoman Lisa Gordon told Bloomberg there are no formal conversations underway and disputed reports that Palantir is considering a deal with Softbank Group Corp. or that the company is seeking as much as $3 billion in funding at a $30 billion valuation.Valuation is a touchy subject for the Silicon Valley company. Although private investors valued Palantir in 2015 at more than $20 billion, aggressive markdowns by mutual funds and an uncertain IPO timeline have taken a toll. Palantir’s valuation has continued to tumble, with shares trading around $5 a share during the past month, according to data from secondary markets.Palantir is very close to breaking even and will end 2019 either slightly in the black or slightly in the red, Thiel said at the briefing. The company will be “significantly in the black” next year, he added.“The judgment call Palantir has made, as have many other companies in Silicon Valley post 2000, is it is often much better to build businesses in private,” Thiel said. “There is some day in the future when Palantir will go public, but we will try to stay private as long as possible.”Palantir’s public image has taken a beating in recent years. It’s attracted scrutiny from privacy advocates and protesters disturbed by the way Palantir’s software has been used by state and local law enforcement in the U.S., as well as by federal agencies like the Department of Homeland Security while implementing the controversial family separation policy at the U.S. Mexican border.Thiel himself has been a lightning rod for criticism, having helped the election of U.S. President Donald Trump in 2016, a divisive decision even within Palantir. That critique could intensify given he has pledged to support Trump’s 2020 re-election.“I envision supporting President Trump over his likely Democratic nominees,” Thiel said in Tokyo, adding he will determine the exact nature of his support as elections approach.(Updates with comments from news briefing from the third paragraph.)To contact the reporters on this story: Pavel Alpeyev in Tokyo at palpeyev@bloomberg.net;Lizette Chapman in San Francisco at lchapman19@bloomberg.netTo contact the editors responsible for this story: Edwin Chan at echan273@bloomberg.net, Vlad SavovFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Zacks
AstraZeneca/Merck's Selumetinib NDA Gets FDA Priority Status
The FDA grants priority review to AstraZeneca (AZN) and Merck's NDA for MEK 1/2 inhibitor, selumetinib. Additionally, Qtrilmet tablets to treat type-II diabetes get approval in the EU.
- Zacks
Pharma Stock Roundup: MRK, GSK, ABBV, LLY's Pipeline & Regulatory Updates
Merck (MRK) gets approval in Europe for Ebola vaccine. Roche, Glaxo (GSK) & Pfizer (PFE) provide pipeline updates.
- Business Wire
BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration
Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (MRK), today announced the U.S. approval of BRAVECTO® PLUS topical solution for cats by the U.S. Food and Drug Administration (FDA). BRAVECTO PLUS is an extended-duration, broad-spectrum combination (fluralaner and moxidectin) topical solution for cats, indicated for both external and internal parasite infestations: ticks and fleas, heartworm, intestinal roundworm and hookworm. This unique formula in BRAVECTO PLUS provides extended protection for up to two months with just one application, making it the only product on the market to protect against this combination of parasites at a longer duration.
- Zacks
4 Big Drugmakers to Bet on After a Great Earnings Season
Big drugmakers post better-than-expected Q3 results, leading to rise in share price of most of the companies in the industry.
- Zacks
Celldex (CLDX) Q3 Loss Narrower Than Expected, Revenues Miss
Celldex (CLDX) reports mixed third-quarter results. Its revenues fall on reduced collaboration and contract revenues.
- Zacks
FDA Panel Votes Against Lilly's Jardiance for Type I Diabetes
Eli Lilly (LLY) gets an unfavorable FDA panel vote to expand the label of its type II diabetes medicine Jardiance (2.5 mg) for type I diabetes.
- Business Wire
US FDA Accepts Regulatory Submission of New Drug Application for Selumetinib in Neurofibromatosis Type 1 (NF1) and Grants Priority Review
AstraZeneca and Merck (MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted priority review for the MEK 1/2 inhibitor selumetinib as a potential new medicine for pediatric patients aged three years and older with neurofibromatosis type 1 (NF1) and symptomatic, inoperable plexiform neurofibromas (PNs).
- Reuters
Merck KGaA raises 2019 guidance after Versum takeover
German science and technology company Merck KGaA raised its full-year forecast for sales and adjusted earnings on Thursday after completing the takeover of semiconductor materials maker Versum Materials in October. Merck said 2019 earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for special items, would come in between 4.23 billion euros and 4.43 billion euros (£3.82 billion), up from a previous prediction of between 4.15 billion euros and 4.35 billion euros. Shares in Merck were down 1.55% at 0828 GMT.
- Reuters - UK Focus
FOCUS-Biotech-for-hire PeptiDream charts new path and becomes short target
The promise of PeptiDream Inc's drug-discovery technology and its lucrative research-for-hire contracts have made it a darling of the Tokyo stock market. Now, those gains have made it a target for short-seller Muddy Waters. The company, which has seen its market value jump fivefold to $6 billion over the past four years, is now pivoting its strategy to in-house research, using its technology that allows it to create libraries of peptide chemicals that can bind drugs to cells.
- Simply Wall St.
Should You Worry About Merck & Co., Inc.'s (NYSE:MRK) CEO Salary Level?
Ken Frazier became the CEO of Merck & Co., Inc. (NYSE:MRK) in 2011. This report will, first, examine the CEO...
- Zacks
Merck's Ebola Vaccine Gets Conditional Approval in Europe
European Commission grants approval to Merck's (MRK) Ervebo (V920) for active immunization of individuals 18 years and above to protect against Ebola Virus Disease caused by Zaire Ebola virus.
- Zacks
Bristol-Myers' Opdivo/Yervoy sBLA for HCC Gets Priority Review
Bristol-Myers' (BMY) label expansion application for Opdivo plus Yervoy combo regimen to include patients with hepatocellular carcinoma, a form of liver cancer, makes progress.
